Skip to content
Screener

Alkermes ALKS Total Equity

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$22.32B+28.0%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$4.53B+8.6%
AbbVie logo
AbbVieABBV
-$6.66B-569%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$54.59M+2.6%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
-$144M+49.5%
LBR
LB Pharmaceuticals IncLBRX
$378.69M+481%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemJune 30, 2026December 31, 2025
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; and zero issued and outstanding at June 30, 2026 and December 31, 2025, respectively.
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 184,700,718 and 181,011,166 shares issued; and 167,541,198 and 165,607,028 shares outstanding at June 30, 2026 and December 31, 2025, respectively1,8471,810
Treasury shares, at cost (17,159,520 and 15,404,138 shares at June 30, 2026 and December 31, 2025, respectively)(502,521)(450,287)
Additional paid-in capital3,112,9203,004,666
Accumulated other comprehensive loss(2,923)(2,100)
Accumulated deficit(800,773)(734,794)
Total shareholders’ equity1,808,5501,819,295
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$4,393,125$2,486,993

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's total equity?
Alkermes (ALKS) reported total equity of $1.81B in Q2 2026.
How has Alkermes's total equity changed year-over-year?
Alkermes's total equity increased by 11.3% year-over-year, from $1.62B to $1.81B.
What is the long-term trend for Alkermes's total equity?
Over 5 years (2020 to 2025), Alkermes's total equity has grown at a 11.3% compound annual growth rate (CAGR), from $1.07B to $1.82B.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Alkermes's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude